The EMA recommended the highest number of approvals in the last 15 years in 2024, giving the nod to 114 drugs. That is amongst the highest number in the 30 years of the agency’s existence, said ...
Teva Pharmaceutical Industries (NYSE:TEVA) said its market applications have been accepted for review by the FDA and European ...
EMA recommends 114 medicines for marketing authorisation; 46 had a new active substance: Amsterdam, The Netherlands Saturday, January 18, 2025, 13:00 Hrs [IST] European Me ...
EMA advisors at the Committee for Medicinal Products for Human Use (CHMP) recommended Sandoz’s adalimumab Humira biosimilar under three brand names – Halimatoz, Hefiya and Hyrimoz. The firm ...
Hosted on MSN1mon
Celltrion biosimilars recommended for EU approvalCelltrion received recommendations of approval from the European drug regulator for four of its biosimilar products ... of the European Medicines Agency (EMA) recommended for market authorization ...
It is the first to approve the biosimilar - although, Tyruko was recommended for approval by EMA advisors in the EU recently and could get the go-ahead there very shortly. Sandoz and Polpharma ...
In acknowledgment of the fact that the EMA does not make recommendations on whether a biosimilar should be used interchangeably with its reference medicine, or with other biosimilar medicines, the ...
Liu: Developing biosimilars in China was challenging a decade ago. The European Medicines Agency (EMA) was the first to introduce guidelines for biosimilars in 2005, and the US FDA launched ...
of the European Medicines Agency (EMA) has adopted positive opinions and recommended marketing authorisations for three biosimilar candidates: Eydenzelt ® (CT-P42, aflibercept), Stoboclo ® and ...
The global remicade biosimilar market is projected to expand significantly between 2025 and 2035, with a market size growing from USD 2.32 billion in 2025 to USD 4.01 billion in 2035, at a robust ...
EQS-News: Formycon AG / Key word (s): Regulatory Approval Formycon receives EU approval for FYB203 (aflibercept), a biosimilar to Eylea®, under the brand names AHZANTIVE® and Baiama® 20.01.2025 / ...
Biosimilars, copies of off-patent biopharmaceuticals ... The European Medicines Agency (EMA) accepted Cinfa Biotech’s B12019 marketing authorization application (MAA) for review in September ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback